Chris Carpenter
Chris Carpenter is an Executive Partner at Sofinnova Investments with over two decades of oncology experience. He focuses on clinical-stage companies and holds board positions at Atsena and Birdseye Therapeutics.
What Chris can write
Sofinnova Investments writes $10M to $30M checks, larger than 97% of firms in the atlas.
Bars: how many firms report each check band. Highlighted: Sofinnova Investments.Career
- Harvard Medical School and the Beth Israel Deaconess Medical Center · led a laboratory
- Merck
- GlaxoSmithKline · Senior Vice President and Head of the Cancer Epigenetics group
- Rubius Therapeutics · Chief Medical Officer
- CatamaranBio · Chief Medical Officer
- Harvard Medical School and the Beth Israel Deaconess Medical Center
- Merck
- Sofinnova · Executive Partner, Private EquityNow
Investments named in public bios
Focus
Education
Also at Sofinnova Investments
Partners like Chris
At firms with a similar stage, sector and check size.
Alert me when Sofinnova Investments is active
One email when Chris's firm raises a fund, adds a partner or shows new activity.
Send Mode VC your deck
Raising a pre-seed or seed round? We write $1M to $5M first checks and help founders with distribution. A partner reads every deck.
Send your deckQuestions
Who is Chris Carpenter?
Chris Carpenter is an Executive Partner at Sofinnova Investments with over two decades of oncology experience. He focuses on clinical-stage companies and holds board positions at Atsena and Birdseye Therapeutics.
How much does Chris Carpenter invest?
Chris Carpenter invests through Sofinnova Investments, which writes checks of $10M to $30M at series a, series b.
How do I pitch Chris Carpenter?
Email [email protected], the firm's inbox for founders, and name Chris in the subject. A warm intro from a founder Sofinnova Investments backed works better.
What did Chris Carpenter do before Sofinnova Investments?
led a laboratory at Harvard Medical School and the Beth Israel Deaconess Medical Center; Merck; Senior Vice President and Head of the Cancer Epigenetics group at GlaxoSmithKline; Chief Medical Officer at Rubius Therapeutics; Chief Medical Officer at CatamaranBio; Harvard Medical School and the Beth Israel Deaconess Medical Center; Merck.
Last updated 2026-10-15. Is this you? Ask for a correction.